Article
Pharmacology & Pharmacy
Ryan J. Keenan, Heather Daykin, Jiahui Chu, Linda Cornthwaite-Duncan, Giancarlo Allocca, Daniel Hoyer, Laura H. Jacobson
Summary: This study investigates the effects of sleep-promoting compounds in transgenic mouse models of tauopathy and finds that these compounds can effectively improve sleep disturbances. The results also suggest that there may be gender differences in the response to hypnotics, which could have implications for the treatment of neurodegenerative disorders in humans.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Article
Clinical Neurology
Tobias Di Marco, Thomas E. Scammell, Michael Meinel, Dalma Seboek Kinter, Alexandre N. Datta, Gary Zammit, Yves Dauvilliers
Summary: The study aimed to explore the effect of daridorexant, a dual orexin receptor antagonist, on nighttime wake bouts and their correlation with daytime functioning. Results showed that daridorexant reduced the number and duration of long wake bouts during the night compared with placebo, corresponding with improved daytime functioning.
Article
Cell Biology
Andrew S. Huhn, Patrick H. Finan, Charlene E. Gamaldo, Alexis S. Hammond, Annie Umbricht, Cecilia L. Bergeria, Eric C. Strain, Kelly E. Dunn
Summary: This study examined the use of a dual-orexin receptor antagonist in opioid withdrawal and found that it may have potential benefits for improving sleep and withdrawal outcomes.
SCIENCE TRANSLATIONAL MEDICINE
(2022)
Article
Clinical Neurology
Brendan P. Lucey, Haiyan Liu, Cristina D. Toedebusch, David Freund, Tiara Redrick, Samir L. Chahin, Kwasi G. Mawuenyega, James G. Bollinger, Vitaliy Ovod, Nicolas R. Barthelemy, Randall J. Bateman
Summary: In this study, it was found that suvorexant, a dual orexin receptor antagonist, acutely decreased tau phosphorylation and amyloid-beta concentrations in the central nervous system. This suggests that suvorexant may have potential as a repurposed drug for the prevention of Alzheimer's disease.
ANNALS OF NEUROLOGY
(2023)
Article
Clinical Neurology
Shadab A. Rahman, Margo D. Nathan, Aleta Wiley, Sybil Crawford, Aviva Y. Cohn, Jessica A. Harder, Leilah K. Grant, Athena Erickson, Akanksha Srivastava, Kathleen McCormick, Suzanne M. Bertisch, John W. Winkelman, Hadine Joffe
Summary: This study suggests that suvorexant is a well-tolerated and effective treatment option for VMS-associated insomnia disorder, reducing nighttime VMS symptoms. However, it did not significantly improve daytime VMS symptoms or other sleep-related outcomes.
Review
Psychiatry
Habibolah Khazaie, Masoud Sadeghi, Sepideh Khazaie, Max Hirshkowitz, Amir Sharafkhaneh
Summary: The study conducted a systematic review and meta-analysis on the treatment of insomnia with suvorexant and lemborexant, showing that both drugs are effective and safe for patients with insomnia.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Clinical Neurology
Thomas A. Mellman, Kiya Birku, Ishaan Sandhu, Pewu Lavela, Ihori Kobayashi
Summary: This study aimed to evaluate the effectiveness of using Zorexant for the treatment of trauma-related insomnia. The results showed that Zorexant can alleviate insomnia symptoms in patients, but there was no significant difference in medication effects. The increased duration of REM segments in the Zorexant group correlated with a reduction in PTSD symptoms.
Article
Psychiatry
Muneto Izuhara, Shoko Miura, Koji Otsuki, Michiharu Nagahama, Maiko Hayashida, Sadayuki Hashioka, Hiroya Asou, Hajime Kitagaki, Masatoshi Inagaki
Summary: This study aimed to use magnetic resonance spectroscopy (MRS) to detect neural and/or glial changes in the VTA to distinguish responders to the orexin receptor antagonist suvorexant. The results showed that the choline/creatine and phosphorylcreatine ratio in the VTA were significantly higher in non-responders compared to responders before suvorexant treatment, with no difference in the N-acetylaspartate/creatine and phosphorylcreatine ratio between the two groups.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Neurosciences
Gary B. Kaplan, Gabrielle A. Lakis, Hryhoriy Zhoba
Summary: This review emphasizes the significance of the orexin neural system in the pathophysiology of PTSD. Orexinergic neurons play a crucial role in fear behaviors, sleep disturbances, and stress responses. Activation of the orexin system is associated with increased fear expression, impaired sleep, and heightened stress.
BRAIN RESEARCH BULLETIN
(2022)
Review
Clinical Neurology
Ting Xiang, Yixian Cai, Zhijin Hong, Jiyang Pan
Summary: In this study, a meta-analysis was conducted to evaluate the effectiveness and safety of Zolpidem in the treatment of insomnia disorder for one month. The results showed that Zolpidem was more effective in increasing total sleep time, reducing sleep latency, and improving sleep quality compared to placebo. There were no significant differences in wake-time after sleep onset and adverse events between Zolpidem and placebo.
Article
Clinical Neurology
Mike Ufer, Debra Kelsh, Kerri A. Schoedel, Jasper Dingemanse
Summary: This study evaluated the abuse potential of daridorexant in healthy recreational sedative drug users. The results showed dose-related drug-liking effects of daridorexant, with lower effects at the highest dose and similar effects at higher doses compared to supratherapeutic doses of suvorexant and zolpidem. The safety and pharmacokinetics of daridorexant were consistent with earlier trials, with quick absorption and elimination.
Article
Pharmacology & Pharmacy
Ishani Landry, Nancy Hall, Jagadeesh Aluri, Gleb Filippov, Larisa Reyderman, Beatrice Setnik, Jack Henningfield, Margaret Moline
Summary: The study aimed to evaluate the abuse potential of Lemborexant, and the results showed that Lemborexant demonstrated similar abuse potential to other drugs and was well tolerated.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
(2022)
Review
Biochemistry & Molecular Biology
Wojciech Ziemichod, Karolina Grabowska, Antonina Kurowska, Grazyna Biala
Summary: This article provides a comprehensive review of daridorexant, including its pharmacodynamics, animal and human research, pharmacokinetics, and safety. Daridorexant is considered a safe hypnotic drug with potential therapeutic effects for insomnia.
Article
Clinical Neurology
Thomas Roth, Russell Rosenberg, Charles M. Morin, Jane Yardley, Kate Pinner, Carlos Perdomo, Norman Atkins, Elizabeth Pappadopulos, Manoj Malhotra, Margaret Moline
Summary: This study evaluated the changes in insomnia severity in subjects with moderate to severe insomnia treated with lemborexant for 12 months. The results showed that lemborexant significantly reduced insomnia severity and increased clinically meaningful response and remission rates.
Article
Chemistry, Organic
Hongshun Yuan, Lei Guo, Xianhua Pan
Summary: An efficient synthetic route for suvorexant without using chiral HPLC separation, resolution, enzyme catalysis or transition metal catalysis is reported, with a total yield up to 37%.
Article
Clinical Neurology
Elahe Zamani, Mehdi Akbari, Shahram Mohammadkhani, John H. Riskind, Christopher L. Drake, Laura Palagini
Summary: This study examined the relationship between neuroticism and reported sleep quality among college students, finding that neuroticism impacts sleep quality through metacognitive, cognitive, and emotional factors. The results highlight the importance of these factors in understanding and addressing sleep quality in this population.
BEHAVIORAL SLEEP MEDICINE
(2022)
Article
Clinical Neurology
David A. Kalmbach, Philip Cheng, Thomas Roth, Leslie M. Swanson, Andrea Cuamatzi-Castelan, Andrea Roth, Christopher L. Drake
Summary: The study found that residual cognitive arousal after treatment was the most robust factor associated with poor response to CBTI. Critically, CBTI responders and non-responders did not differ on other sociodemographic or pretreatment metrics. Postpartum, short sleep duration (<6 hrs/night) was linked to maternal reports of poor infant sleep quality.
BEHAVIORAL SLEEP MEDICINE
(2022)
Article
Clinical Neurology
David A. Kalmbach, Louise M. O'Brien, D'Angela S. Pitts, Chaewon Sagong, Lily K. Arnett, Nicholas C. Harb, Philip Cheng, Christopher L. Drake
Summary: The study revealed that maternal and infant sleep problems are associated with impaired mother-to-infant bonding, with nighttime cognitive hyperarousal and daytime sleepiness potentially serving as facilitating mechanisms. Other factors such as prenatal snoring and weak maternal-fetal attachment were also found to predict poorer postpartum bonding, highlighting the importance of improving maternal and infant sleep to enhance the mother-infant relationship.
BEHAVIORAL SLEEP MEDICINE
(2022)
Article
Clinical Neurology
Philip Cheng, Melynda D. Casement, David A. Kalmbach, Andrea Cuamatzi Castelan, Christopher L. Drake
Summary: This study found that dCBT-I treatment can enhance patients' self-efficacy in managing insomnia symptoms, resulting in reduced insomnia and depressive symptoms during the COVID-19 pandemic. Self-efficacy plays a crucial role in preventing insomnia and depressive symptoms, contributing to predicting future sleep and mental health.
BEHAVIORAL SLEEP MEDICINE
(2022)
Article
Psychology, Clinical
Philip Cheng, David A. Kalmbach, Hsing-Fang Hsieh, Andrea Cuamatzi Castelan, Chaewon Sagong, Christopher L. Drake
Summary: This study examined the role of resilience as a mediator of treatment outcomes in insomnia patients. The results showed that participants who received digital cognitive behavioral therapy for insomnia had greater improvements in resilience compared to those in the sleep education control group. Improved resilience was associated with reduced risk of insomnia relapse and incident depression at 1-year follow-up.
PSYCHOLOGICAL MEDICINE
(2023)
Article
Clinical Neurology
Anthony N. Reffi, Christopher L. Drake, David A. Kalmbach, Tanja Jovanovic, Seth D. Norrholm, Thomas Roth, Melynda D. Casement, Philip Cheng
Summary: This study examines how pre-pandemic sleep reactivity predicts stress reactions and depression during the COVID-19 pandemic. It finds that higher pre-pandemic sleep reactivity is associated with more stress reactions and depression. Additionally, digital cognitive behavioural therapy for insomnia mitigates the relationship between pre-pandemic sleep reactivity and stress reactions.
JOURNAL OF SLEEP RESEARCH
(2023)
Article
Clinical Neurology
Diana Haggerty, Dawn A. Contreras, Anita Carter, Christopher Drake, Robin M. Tucker
Summary: This study confirmed that the positive effects obtained from a community-delivered sleep education program were maintained six months after the program completion. The intervention improved sleep quality, duration, insomnia symptoms, and sleep hygiene behaviors, suggesting its potential as a tool to address uncomplicated sleep issues.
BEHAVIORAL SLEEP MEDICINE
(2023)
Editorial Material
Clinical Neurology
David A. Kalmbach, Julio Fernandez-Mendoza, Christopher L. Drake
Article
Clinical Neurology
David A. Kalmbach, Philip Cheng, Anthony N. Ref, Grace M. Seymour, Melissa K. Ruprich, Luisa F. Bazan, D'Angela S. Pitts, Olivia Walch, Christopher L. Drake
Summary: In the United States, Black women are more likely to suffer from prenatal insomnia. Cognitive-behavioral therapy for insomnia (CBTI) may help reduce this disparity, but racial minorities, including Black pregnant women, have lower treatment engagement and poorer outcomes compared to white patients. This study examined differences in treatment engagement and patient-reported outcomes in non-Hispanic Black and white pregnant women receiving digital CBTI.
Review
Clinical Neurology
Anthony N. Reffi, David A. Kalmbach, Philip Cheng, Christopher L. Drake
Summary: Sleep reactivity refers to a predisposition to sleep disturbance during environmental perturbations, pharmacological challenges, or stressful life events. Individuals with high sleep reactivity are prone to insomnia disorder after a stressor, increasing the risk of psychopathology and hindering recovery from traumatic stress. It is important to ameliorate sleep reactivity to prevent insomnia and promote resilience to adversity.
JOURNAL OF SLEEP RESEARCH
(2023)
Article
Clinical Neurology
Omer Faruk Uygur, Oli Ahmed, Aynur Bahar, Onur Hursitoglu, Esat Fahri Aydin, Seockhoon Chung, Halil Ozcan, Christopher L. Drake
Summary: The study aimed to adapt and validate the Ford Insomnia Response to Stress Test (FIRST-T) in Turkish university students. The results showed that the FIRST-T had good reliability and validity in this population, and could differentiate between individuals with severe insomnia and good sleepers.
NATURE AND SCIENCE OF SLEEP
(2023)
Article
Clinical Neurology
Philip Cheng, Sara Santarossa, David Kalmbach, Chaewon Sagong, Kristen Hu, Christopher Drake
Summary: Digital cognitive behavioral therapy has advantages for insomnia, but only half of the patients can achieve remission. Treatment engagement is critical for its effectiveness, and barriers disproportionately affect under-resourced communities. Identifying facilitators and barriers is important for its scalability.
Article
Health Care Sciences & Services
Emerson M. Wickwire, Jacob Collen, Vincent F. Capaldi, Scott G. Williams, Samson Z. Assefa, Julianna P. Adornetti, Kathleen Huang, Janet M. Venezia, Rachell L. Jones, Christine W. Johnston, Connie Thomas, Mary Ann Thomas, Charles Mounts, Christopher L. Drake, Michael S. Businelle, Michael A. Grandner, Rachel Manber, Jennifer S. Albrecht
Summary: This study evaluated patient engagement and provider perceived effectiveness of a novel sleep telehealth platform and remote monitoring assessment in the US military. The results indicated that military patients with sleep problems and primary care providers demonstrated high levels of engagement and satisfaction with the sleep telehealth platform. This approach has the potential to increase access to evidence-based sleep medicine care in the military.
JMIR FORMATIVE RESEARCH
(2023)
Meeting Abstract
Neurosciences
Philip Cheng, Sara Santarossa, David Kalmbach, Christopher Drake
BIOLOGICAL PSYCHIATRY
(2022)
Meeting Abstract
Geriatrics & Gerontology
Christopher Drake, Jane Yardley, Kate Pinner, Margaret Moline
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY
(2022)